NCT04293185: An ongoing trial by bluebird bio
This trial is ongoing. It must report results 2 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04293185 |
|---|---|
| Title | A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 14, 2020 |
| Completion date | May 31, 2027 |
| Required reporting date | May 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |